Barrow to Participate in First Platform Trial for ALS
Every 90 minutes, someone learns they have ALS and another person dies from the disease. People with ALS live about two to five years on average, and existing medications can only moderately slow the progression….
Study Shows ALS Patients May Benefit From More Glucose
A study co-authored by Barrow researchers Dr. Rita Sattler and Dr. Robert Bowser found that people with amyotrophic lateral sclerosis (ALS) may benefit from more glucose. It is widely known that people with the neurodegenerative…
Dr. Jeremy Shefner Announces Results of FORTITUDE-ALS Trial
Dr. Jeremy Shefner, chair of the Department of Neurology at Barrow, recently presented the results of the FORTITUDE-ALS trial at the annual meeting of the American Academy of Neurology in Philadelphia. The Phase 2 trial…
Barrow, CloudMedx to Use AI to Better Understand ALS Progression
The Gregory W. Fulton ALS and Neuromuscular Disease Center at Barrow is collaborating with a healthcare artificial intelligence (AI) company to track disease progression in people with amyotrophic lateral sclerosis (ALS). Currently, little is known…
